Maxcyte, Inc.
A maker of electroporation instruments and technology that help scientists slip genetic material like mRNA and DNA into living cells — a key step in building cell and gene therapies and vaccines. Its Flow Electroporation platform is used by biopharma companies and researchers to engineer cells for treating disease. Founded in 1999 in Gaithersburg, Maryland, the company's name blends "maximum" and "cyte" (the Greek root for cell), reflecting its goal of getting the most out of every engineered cell.
Sold 3.97M
Granted 375.0K · Bought 175.0K · Sold 75.0K
Granted 224.1K · Bought 100.0K · Sold 143.1K
Granted 21.4K
Granted 560.0K · Sold 660.0K
Granted 81.0K · Bought 180.0K
Granted 172.0K · Sold 91.0K
Granted 187.5K
Granted 81.0K · Bought 50.0K
Granted 118.8K · Bought 50.0K · Sold 17.1K
Granted 125.0K · Sold 150.0K
Granted 111.3K
Granted 81.0K
Granted 81.0K
Granted 81.0K · Sold 10.7K
Granted 27.0K · Sold 4.8K
Granted 45.0K · Sold 1.2K
Granted 454.0K · Sold 429.0K
Granted 150.0K · Sold 150.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Casdin Eli +3 co-filers10% owner · 2 transactions | -17.8% | 10.00Mas of Oct 2022 | — | — | 3.97M |
| Masoud MaherPresident and CEO, Director · 11 transactions | — | 475.0K | 375.0K | 175.0K | 75.0K |
| Erck Stanley CDirector · 14 transactions | +73.1% | 428.7K | 224.1K | 100.0K | 143.1K |
| Mandell ArtDirector · 1 transaction | +5.7% | 395.9Kas of Jun 2024 | 21.4K | — | — |
| Doerfler DouglasPresident and CEO, Director · 52 transactions | -23.1% | 333.2Kas of Dec 2023 | 560.0K | — | 660.0K |
| Douglas RichardDirector · 6 transactions | — | 261.0K | 81.0K | 180.0K | — |
| Johnston John JosephDirector · 50 transactions | +67.2% | 201.6K | 172.0K | — | 91.0K |
| Ahuja ParmeetChief Financial Officer · 1 transaction | — | 187.5K | 187.5K | — | — |
| Brooke William WDirector · 4 transactions | +260.4% | 181.3K | 81.0K | 50.0K | — |
| Swirsky Douglas JCHIEF FINANCIAL OFFICER · 5 transactions | — | 151.7K | 118.8K | 50.0K | 17.1K |
| Holtz RonSVP and CAO · 6 transactions | -16.6% | 125.3Kas of Nov 2021 | 125.0K | — | 150.0K |
| Collins CynthiaDirector · 3 transactions | — | 111.3K | 111.3K | — | — |
| Al-Wakeel Yasir B.Director · 3 transactions | — | 81.0K | 81.0K | — | — |
| Balthrop Patrick JDirector · 3 transactions | — | 81.0K | 81.0K | — | — |
| Hemrajani RekhaDirector · 4 transactions | — | 70.3K | 81.0K | — | 10.7K |
| Sandoval David I.GENERAL COUNSEL · 4 transactions | — | 64.2Kas of Mar 2025 | 27.0K | — | 4.8K |
| Soleymannezhad AliChief Commercial Officer · 3 transactions | — | 59.4Kas of Mar 2025 | 45.0K | — | 1.2K |
| Ross Thomas M.EVP, GLOBAL SALES · 57 transactions | — | 42.9Kas of Aug 2024 | 454.0K | — | 429.0K |
| Murphy Amanda LouiseChief Financial Officer · 6 transactions | — | 37.3Kas of Nov 2021 | 150.0K | — | 150.0K |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last 5 years: -5.15M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.